Apr 16 |
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
|
Apr 15 |
Amneal Pharmaceuticals (NASDAQ:AMRX) shareholders are still up 235% over 1 year despite pulling back 8.0% in the past week
|
Apr 6 |
Bausch Health sues Amneal Pharma over Xifaxan generic
|
Mar 28 |
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
|
Mar 25 |
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
|
Mar 1 |
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript
|
Mar 1 |
Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
|
Mar 1 |
Amneal Pharmaceuticals Inc (AMRX) Reports Mixed 2023 Financial Results
|
Mar 1 |
Amneal Pharmaceuticals Non-GAAP EPS of $0.14 beats by $0.05, revenue of $617M misses by $17.86M
|
Mar 1 |
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
|